Disease · HP_0000999

Pyoderma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Pyoderma. Diseases, record HP_0000999. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000999

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Pyoderma; Open Targets
Open Targets ID: HP_0000999; Open Targets
Other names: Pus-filled lesion; Open Targets
Disease Ontology: DOID:4223; Disease Ontology
Highest stage of its drugs: Approval, for 1 of its 12 drugs, from PMDA; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TIGECYCLINE	CHEMBL376140	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
GEVOKIZUMAB	CHEMBL1743026	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
VILOBELIMAB	CHEMBL2109636	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
OXYGEN	CHEMBL1234886	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BERMEKIMAB	CHEMBL2109653	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CANAKINUMAB	CHEMBL1201834	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ETRASIMOD	CHEMBL3358920	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IXEKIZUMAB	CHEMBL1743034	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IL17A	Interleukin-17A	2	Interleukin 17A inhibitor	Phase 2	https://conductscience.org/library/genes/3605	Drugs and targets
IL1B	Interleukin-1 beta	2	Interleukin-1 beta inhibitor; Interleukin-1 beta negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/3553	Drugs and targets
C5	Complement C5	1	Complement C5 inhibitor	Phase 3	https://conductscience.org/library/genes/727	Drugs and targets
IL1A	Interleukin-1 alpha	1	Interleukin-1 alpha inhibitor	Phase 2	https://conductscience.org/library/genes/3552	Drugs and targets
IL1RAP	IL36 receptor	1	IL36 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3556	Drugs and targets
IL36R	IL36 receptor	1	IL36 receptor antagonist	Phase 2	https://conductscience.org/library/genes/8808	Drugs and targets
S1PR1	Sphingosine 1-phosphate receptor 1	1	Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-1 modulator	Phase 2	https://conductscience.org/library/genes/1901	Drugs and targets
S1PR4	Sphingosine 1-phosphate receptor 4	1	Sphingosine 1-phosphate receptor Edg-6 modulator	Phase 2	https://conductscience.org/library/genes/8698	Drugs and targets
S1PR5	Sphingosine 1-phosphate receptor 5	1	Sphingosine 1-phosphate receptor Edg-8 modulator	Phase 2	https://conductscience.org/library/genes/53637	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7124	Drugs and targets

1 to 10 of 11

See all 11 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03971643	Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum	Phase 2	19	2023-09-14	Pyoderma Gangrenosum	VILOBELIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03137160	An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	Phase 2	4	2022-06-06	Pyoderma Gangrenosum	IXEKIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03072953	Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum	Phase 2	2	2021-06-11	Pyoderma Gangrenosum	ETRASIMOD	Open Targets' reading of its record	ClinicalTrials.gov
NCT05964413	Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum	Phase 3	54		Pyoderma Gangrenosum	VILOBELIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03311464	A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan	Phase 3	22		Pyoderma Gangrenosum	ADALIMUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02315417	An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Phase 3	16		Pyoderma Gangrenosum	GEVOKIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02318914	A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum	Phase 3	15		Pyoderma Gangrenosum	GEVOKIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01965613	A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum	Phase 2	10		Pyoderma Gangrenosum	BERMEKIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02326740	An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Phase 3	9		Pyoderma Gangrenosum	GEVOKIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01882504	Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum	Phase 2	8		Pyoderma Gangrenosum	GEVOKIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000999

GET https://conductscience.org/api/diseases/v1/HP_0000999/drugs

API reference For AI assistants